Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. (CDTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CDTX · as of Sep 30, 2025
Ownership Breakdown
179
Institutional Holders
▲ 57 vs Q2
$3.11B
Total Inst. Value
▲ $1.85B vs Q2
25.36M
Shares Outstanding
freeFloat 76.40%
32.49M
13F Shares Held
▲ 6.58M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CDTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 3.37M | 21.65% | 21.65% | $322.28B | Nov 14, 2025 | — held |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC biological products, (no diagnostic substances) | 3.02M | 19.43% | 19.43% | $289.29B | Nov 14, 2025 | ▲ 520.3K |
POINT72 ASSET MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.58M | 10.15% | 10.15% | $151.12B | Nov 14, 2025 | ▲ 50.1K |
BVF INC/IL biological products, (no diagnostic substances) | 1.41M | 9.10% | 9.10% | $135.42B | Nov 14, 2025 | ▲ 627.8K |
VIVO CAPITAL, LLC biological products, (no diagnostic substances) | 1.31M | 8.44% | 8.44% | $125.58B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.23M | 7.92% | 7.92% | $117.85B | Nov 7, 2025 | ▲ 264.0K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.17M | 7.50% | 7.50% | $111.60B | Nov 12, 2025 | ▲ 57.8K |
DARWIN GLOBAL MANAGEMENT, LTD. biological products, (no diagnostic substances) | 997.2K | 6.41% | 6.41% | $94.99B | Nov 14, 2025 | ▲ 228.8K |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 961.2K | 6.18% | 6.18% | $92.04B | Nov 14, 2025 | NEW |
VR ADVISER, LLC biological products, (no diagnostic substances) | 946.8K | 6.09% | 6.09% | $90.66B | Nov 14, 2025 | ▲ 307.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
30
Increased
+6.26M shares7
New Positions
first time holders10
Decreased
−2.33M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.93M
+6.26M / −2.33M
Net new holders
+27
7 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CDTX insider trading · insider activity
Source: SEC Form 4
1
Buy transactions
90
Sell transactions
0.01
Buy/Sell ratio
$8M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P.
| Jan 7, 2026 | D-Return | 89,956 | — | — | 0 | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P.
| Jan 7, 2026 | D-Return | 4,652,309 | $221.50 | $1.03B | 0 | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P.
| Jan 7, 2026 | D-Return | 5,079 | $21.31 | $108.2K | 0 | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P.
| Jan 7, 2026 | D-Return | 22,200 | $26.62 | $591.0K | 0 | Form 4 ↗ |
Resnick Joshua director | Jan 7, 2026 | D-Return | 5,079 | $21.31 | $108.2K | 0 | Form 4 ↗ |
Resnick Joshua director | Jan 7, 2026 | D-Return | 22,200 | $26.62 | $591.0K | 0 | Form 4 ↗ |
Spencer Ryan director | Jan 7, 2026 | D-Return | 2,125 | $12.64 | $26.9K | 0 | Form 4 ↗ |
Spencer Ryan director | Jan 7, 2026 | D-Return | 11,100 | $21.31 | $236.5K | 0 | Form 4 ↗ |
Spencer Ryan director | Jan 7, 2026 | D-Return | 4,250 | $12.63 | $53.7K | 0 | Form 4 ↗ |
Merson James director | Jan 7, 2026 | D-Return | 4,250 | $12.63 | $53.7K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cidara Therapeutics, Inc. (CDTX) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 23.60%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Cidara Therapeutics, Inc. is RA CAPITAL MANAGEMENT, L.P., holding approximately 3.37 million shares — equal to 21.65% of outstanding shares — as of September 30, 2025.
A total of 179 institutional investors currently hold CDTX stock, with a combined institutional value of approximately $3.11 billion as of the most recent 13F filing period.
Frequently asked questions
CDTX ownershipCidara Therapeutics, Inc. (CDTX) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 21.65% stake. Company insiders hold 23.60%. Data sourced from SEC Form 13F as of September 30, 2025.